Clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis

Current effective version

PDF iconAdopted guideline

Reference numberEMA/531686/2015, Corr.1
Effective from01/06/2016
KeywordsAmyotrophic lateral sclerosis (ALS), motor neuron disease
DescriptionThis document provides guidance on the clinical investigation of medicinal products for the treatment of myotrophic lateral sclerosis. It focuses on the design of studies for disease-modifying as well as symptomatic treatments, the choice of meaningful outcome parameters and the clinical relevance of functional tests of disability including motor and respiratory functions and their relationship to survival.

Document history

First version

Current version

PDF iconAdopted guideline

PDF iconOverview of comments

PDF iconDraft guideline

PDF iconConcept paper

In operation: 01/06/2016

Published: 01/02/2016

Published: 01/08/2013

Published: 30/03/2012

Superseded document PDF iconAdopted guideline Published: 19/10/2000

Related content

How useful was this page?

Add your rating